Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Neumora Advances to Phase III with Depression Drug, Hires AbbVie Vet as CEO
Neumora Snaps Up $112M to Advance Precision Neuroscience Work Through Clinic
Pretzel Gets $72.5M for Gene Editing & Small Molecules Against Mitochondrial Targets
Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs